Ligand Pharmaceuticals INC Form 4 insider transactions

Matthew Korenberg, President & Chief Operating Officer of Ligand Pharmaceuticals, acquired 350 shares of common stock through the company's Employee Stock Purchase Plan on June 28, 2024.

Octavio Espinoza, CFO of Ligand Pharmaceuticals, reports acquiring 267 shares of common stock through the company's Employee Stock Purchase Plan.

Ligand Pharmaceuticals CEO Todd C. Davis acquired 350 shares of common stock through the company's Employee Stock Purchase Plan on June 28, 2024.

Director Stephen L. Sabba reports acquisition of Ligand Pharmaceuticals stock and options via grant.

Director Martine Zimmermann reports acquiring 1,252 shares of common stock and 5,444 non-qualified stock options from Ligand Pharmaceuticals on June 14, 2024.

Director John L. LaMattina reports acquisition of stock options and restricted stock units in Ligand Pharmaceuticals.

Director John W. Kozarich reports acquisition of Ligand Pharmaceuticals stock and options through board grant.

Director Jason Haas acquired Ligand Pharmaceuticals stock and stock options on June 14, 2024, according to a Form 4 filing.

Director Nancy Ryan Gray reports acquisition of stock options and restricted stock units in Ligand Pharmaceuticals.

Director Jason Aryeh reports acquisition of restricted stock units and stock options in Ligand Pharmaceuticals.

Director Nancy Ryan Gray sold 934 shares of Ligand Pharmaceuticals (LGND) at a weighted-average price of $83.2049 on May 9, 2024.

Octavio Espinoza, CFO of Ligand Pharmaceuticals, reports multiple transactions involving the acquisition and disposal of common stock and derivative securities.

Matthew Korenberg, President & Chief Operating Officer of Ligand Pharmaceuticals, sold a total of 17,598 shares of common stock in multiple transactions on May 13 and 14, 2024.

Andrew Reardon, Chief Legal Officer of Ligand Pharmaceuticals, exercised stock options and sold 10,000 shares of common stock on May 9, 2024.

Jason Aryeh, a director at Ligand Pharmaceuticals, exercised non-qualified stock options, acquiring 2,406 shares of common stock at $52.30 on April 30, 2024.

John W. Kozarich, a director at Ligand Pharmaceuticals, exercised stock options on April 24, 2024, acquiring 2,893 shares of common stock at $39.35 per share.

CEO Todd C. Davis exercised stock options on March 25, 2024, increasing his direct ownership of Ligand Pharmaceuticals' common stock.

Director Stephen Sabba reports acquisition and disposal of Ligand Pharmaceuticals stock and derivative securities.

Jason Aryeh, a director at Ligand Pharmaceuticals, exercised stock options on March 5, 2024, acquiring 2,893 shares at $39.35.

Andrew Reardon, Chief Legal Officer of Ligand Pharmaceuticals, reports acquisition of stock options and restricted stock units.

Matthew Korenberg, President & COO of Ligand Pharmaceuticals, reports the acquisition of restricted stock units and stock options.

Octavio Espinoza, CFO of Ligand Pharmaceuticals, reports acquisition and disposal of common stock and derivative securities, including stock options and restricted stock units.

CEO Todd C. Davis reports acquisition of restricted stock units and stock options in Ligand Pharmaceuticals.